EdgarLookup

Tango Therapeutics, Inc. — Quarterly Financials

Quarterly figures from SEC EDGAR XBRL filings (10-Q)

These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Tango Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.

Overview All Filings Annual Quarterly Insiders

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 $53.81M Nov 4, 2025
Q2 2025 Jun 30, 2025 $3.18M Aug 5, 2025
Q1 2025 Mar 31, 2025 $5.39M May 12, 2025
Q3 2025 Sep 30, 2024 $11.61M Nov 4, 2025
Q2 2025 Jun 30, 2024 $19.88M Aug 5, 2025
Q1 2025 Mar 31, 2024 $6.47M May 12, 2025
Q3 2024 Sep 30, 2023 $10.73M Nov 6, 2024
Q2 2024 Jun 30, 2023 $14.60M Aug 7, 2024
Q1 2024 Mar 31, 2023 $5.77M May 8, 2024
Q3 2023 Sep 30, 2022 $6.92M Nov 8, 2023
Q2 2023 Jun 30, 2022 $5.77M Aug 7, 2023
Q1 2023 Mar 31, 2022 $5.76M May 9, 2023
Q3 2022 Sep 30, 2021 $6.79M Nov 10, 2022
Q2 2022 Jun 30, 2021 $18.15M Aug 10, 2022
Q1 2022 Mar 31, 2021 $6.39M May 11, 2022
Q3 2021 Sep 30, 2020 ($11.26M) Nov 9, 2021

Net Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 $15.88M Nov 4, 2025
Q3 2025 Jun 30, 2025 ($38.85M) Nov 4, 2025
Q2 2025 Jun 30, 2025 ($38.85M) Aug 5, 2025
Q3 2025 Mar 31, 2025 ($39.88M) Nov 4, 2025
Q2 2025 Mar 31, 2025 ($39.88M) Aug 5, 2025
Q1 2025 Mar 31, 2025 ($39.88M) May 12, 2025
Q3 2025 Sep 30, 2024 ($29.17M) Nov 4, 2025
Q3 2025 Jun 30, 2024 ($25.55M) Nov 4, 2025
Q2 2025 Jun 30, 2024 ($25.55M) Aug 5, 2025
Q1 2025 Mar 31, 2024 ($37.91M) May 12, 2025
Q2 2025 Mar 31, 2024 ($37.91M) Aug 5, 2025
Q3 2025 Mar 31, 2024 ($37.91M) Nov 4, 2025
Q3 2024 Sep 30, 2023 ($22.26M) Nov 6, 2024
Q2 2024 Jun 30, 2023 ($20.71M) Aug 7, 2024
Q3 2024 Jun 30, 2023 ($20.71M) Nov 6, 2024
Q2 2024 Mar 31, 2023 ($28.01M) Aug 7, 2024
Q3 2024 Mar 31, 2023 ($28.01M) Nov 6, 2024
Q1 2024 Mar 31, 2023 ($28.01M) May 8, 2024
Q3 2023 Sep 30, 2022 ($29.05M) Nov 8, 2023
Q2 2023 Jun 30, 2022 ($24.86M) Aug 7, 2023

Operating Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 $14.07M Nov 4, 2025
Q2 2025 Jun 30, 2025 ($40.97M) Aug 5, 2025
Q1 2025 Mar 31, 2025 ($42.53M) May 12, 2025
Q3 2025 Sep 30, 2024 ($32.88M) Nov 4, 2025
Q2 2025 Jun 30, 2024 ($29.55M) Aug 5, 2025
Q1 2025 Mar 31, 2024 ($42.26M) May 12, 2025
Q3 2024 Sep 30, 2023 ($25.63M) Nov 6, 2024
Q2 2024 Jun 30, 2023 ($23.25M) Aug 7, 2024
Q1 2024 Mar 31, 2023 ($30.29M) May 8, 2024
Q3 2023 Sep 30, 2022 ($29.92M) Nov 8, 2023
Q2 2023 Jun 30, 2022 ($25.20M) Aug 7, 2023
Q1 2023 Mar 31, 2022 ($25.38M) May 9, 2023
Q3 2022 Sep 30, 2021 ($19.57M) Nov 10, 2022
Q2 2022 Jun 30, 2021 ($4.56M) Aug 10, 2022
Q1 2022 Mar 31, 2021 ($12.08M) May 11, 2022
Q3 2021 Sep 30, 2020 ($26.76M) Nov 9, 2021
Q2 2021 Jun 30, 2020 ($472) Aug 9, 2021